Find Funding Opportunities

The purpose of this Notice is to inform potential applicants of the NIHs interest in supporting research on interventions designed to change the culture to mitigate or eliminate sexual harassment in the biomedical research enterprise. This notice aligns with the Anti-Sexual Harassment policy notice released by NIH as well as recommendations made in the December 2019 Report from the Working Group to the Advisory Committee to the NIH Director on Changing the Culture to End Sexual Harassment.

SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research NOT-OD-20-031 with an emphasis on providing students with research opportunities and enriching the research environment at the applicant institutions. ?The purpose of SuRE awards is to provide research grant support for faculty investigators at eligible institutions who haveprior experience in leading externally-funded, independent research butare not currently funded by any NIH Research Project Grants with the exception of SuRE or SuRE-First awards.

SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research (see NOT-OD-20-031) with an emphasis on providing students with research opportunities and enriching the research environments at the applicant institutions. The purpose of SuRE-First awards is to support research grants for faculty investigators at eligible institutions who have not had prior independent external research grants.

This NINDS Notice of Special Interest (NOSI) announces the availability of administrative supplements to support hyperacute magnetic resonance imaging (MRI) of the brain in stroke patients to understand how lesion evolution and hyperacute brain changes affect cognitive trajectories and outcomes.

This notice informs applicants of a change to the Key Dates for PA-18-705 "SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed)". This Funding Opportunity Announcement (FOA) has been extended by one additional council round to expire on September 6, 2021. Due to the extension, the following date has been added: New, Renewal, Resubmission, and Revision Application Due Date: September 5, 2021. The following section of PA-18-705 "SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed)" has been modified, as indicated below.

Between 40 and 70% of older adults suffer from sleep disturbances or disorders, which are especially prevalent among patients with Alzheimer's Disease and Alzheimers Disease Related Dementias (AD/ADRD), i.e., frontotemporal dementia, Lewy body dementia, vascular contributions to cognitive impairment and dementia, and multiple etiology dementias. The AD Research Summits specifically recommends to invest in understanding the integrative physiology of sleep and elucidating the short- and long-term consequences of disrupted and optimized sleep on brain aging and AD. Moreover, NIAs AD/ADRD Research Implementation Milestone 2.F plans to "create new research programs aimed at understanding the integrative physiology of circadian rhythms and sleep and its impact on brain aging and the risk of AD and AD-related dementias at multiple levels (epigenetic, gene expression, proteomic, neuronal, network, systems) to identify new targets and approaches for AD prevention." The purpose of this one-year administrative supplement program is to facilitate collaborative research to better understand the bi-directional relationship between chronic sleep disturbances/circadian disruption and AD/ADRD pathogenesis. This notice encourages eligible NINDS awardees in the AD/ADRD research community to apply for supplemental funds to establish new collaborations with sleep/circadian researchers for the advancement of research on the association between sleep disturbances/circadian disruption with ADRD. This initiative aims to investigate the potential of sleep/circadian-related treatment as a modifier of the development and progression of neurodegeneration. The proposed studies must be within the scope of the peer-reviewed activities specified within the NINDS parent award, and collaborators may not have a prior history of collaboration. Active awards with project end dates in FY 2022 or later are eligible. The award may not be entering or in a terminal no-cost extension in FY 2021.

NINDS is interested in supplementing applications to conduct research on the effects of COVID-19 on the development of, or disease progression in, AD/ADRD. For example, anosmia is a risk factor for developing LBD and AD dementiaand anosmia is a common sequelae of COVID-19 infection, but it is unclear whether COVID-19 infected individuals with anosmia are also at greater risk for developing cognitive impairment and dementia. Similarly, although subjects with AD/ADRD are likely to worsen cognitively during COVID-19 infection, research is lacking as to whether they return to baseline after recovery from infection or whether there is accelerated progression of cognitive decline. Applicants requesting supplements to active NINDS-funded human subjects projects that will address these research questions, for example bytesting for COVID-19, anosmia, cognitive assessments, and biomarker assessments (neuroimaging, fluid-based), are encouraged under this opportunity.

The purpose of this one-year administrative supplement is to expand the scope of the currently active awards supported by the Blueprint RFAs on the Neurobiology of Small Blood and Lymphatic Vessels (RFAs NS-18-003 and NS-18-004) to advance the mechanistic understanding and/or the development of new technologies to investigate changes in brain small vessels that can lead to Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD). Areas of interest include: alterations in the brain (g)lymphatic system, cerebral microinfarcts and microbleeds, post-stroke cognitive impairment, and vascular contributions to cognitive impairment and dementia, with an emphasis on the microvasculature.

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The proposal must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.